Brief: Lidds Licensee Prepares For Phase III Trial In China
07/11/2019 08:58
Nov 7 (Reuters) - Lidds AB LIDDS.ST :
* REG-LIDDS LICENSEE JIANGXI PUHENG PHARMA PREPARES FOR
PHASE III
TRIAL IN CHINA
* JIANGXI PUHENG PHARMA INITIATED DISCUSSIONS WITH CHINESE
MEDICAL
AUTHORITY, CFDA.
* PHASE III CLINICAL TRIAL WILL BE CONDUCTED IN UROLOGY
CLINICS IN
CHINA AND WILL BE FULLY FINANCED BY JIANGXI PUHENG PHARMA
Source text for Eikon: ID:nGNE7g1Kdg
Further company coverage: LIDDS.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest